About: Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty?
Creator	Torresani, Erminio Grossi, Claudia Tedesco, Francesco Andreoli, Laura Brugnoni, Duilio Franceschini, Franco Garrafa, Emirena Lazzaroni, Maria Masneri, Stefania Meroni, Pier Muiesan, Maria Piantoni, Silvia Pozzi, Nicola Salvetti, Massimo Tincani, Angela Beltagy, Asmaa Blengino, Simonetta Bodio, Caterina Borghi, Maria Cecchini, Germana Crisafulli, Francesca Curreli, Daniele Heilbron, Francesca Mahler, Michael Parati, Gianfranco Pengo, Martino Pregnolato, Francesca
Source	MedRxiv; Medline
abstract	Background. Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-{beta}2GPI and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-{beta}2GPI antibodies was not reported. Aim. To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-{beta}2GPI antibodies. Methods. ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events. Results. Anti-{beta}2GPI IgG/IgA/IgM were the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM were detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of {beta}2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-{beta}2GPI nor with thrombosis. Conclusion. aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against {beta}2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.1101/2020.06.17.20134114
bibo:pmid	32588001
has license	medrxiv
sha1sum (hex)	d94c94aa9991aaee08c9d407610dd91c7f7c35d0
schema:url	https://doi.org/10.1101/2020.06.17.20134114
resource representing a document's title	Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty?
has PubMed identifier	32588001
schema:publication	medRxiv : the preprint server for health sciences
resource representing a document's body	covid:d94c94aa9991aaee08c9d407610dd91c7f7c35d0#body_text
is schema:about of	named entity 'BUT' named entity 'Prevalence' named entity 'antibodies' named entity 'anti-phospholipid antibodies' named entity 'glycoprotein' named entity 'CIA' named entity 'epitope' named entity 'aPL' named entity 'Descriptive statistics' named entity 'systemic autoimmune diseases' named entity 'Critically ill patients' named entity 'aPL' named entity 'thrombotic events' named entity 'IgG' named entity 'thrombosis' named entity 'thrombosis' named entity 'antibodies' named entity 'COVID' named entity 'thrombotic events' named entity 'COVID' named entity 'Brescia' named entity 'aPL' named entity 'aPL' named entity 'antibodies' named entity 'high levels' named entity 'COVID' named entity 'antibodies' named entity 'organ failure' named entity 'titer' named entity 'phospholipid' named entity 'false positive results' named entity 'aPTT' named entity 'Milan' named entity 'anticoagulant' named entity 'aPTT' named entity 'aPL' named entity 'IgM' named entity 'COVID-19' named entity 'IgG' named entity 'Fisher's exact test' named entity 'D-dimer' named entity 'IgA' named entity 'autoantibodies' named entity 'aPL' named entity 'CIA' named entity 'HIV' named entity 'COVID' named entity 'medRxiv' named entity 'high levels' named entity 'diagnostic tools' named entity 'current literature' named entity 'medRxiv' named entity 'antibodies' named entity 'thromboplastin' named entity 'aPTT' named entity 'placenta'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software